Tools for Practice Outils pour la pratique


#164 Alpha blockers for BPH-LUTS: Let it flow or still slow?


CLINICAL QUESTION
QUESTION CLINIQUE
How effective are alpha-blockers in reducing lower urinary tract symptoms (LUTS) in men with benign prostatic hypertrophy (BPH)?


BOTTOM LINE
RÉSULTAT FINAL
Alpha-blockers are effective as first line therapy for LUTS-BPHCompared to placebo, around 1 in 10 will have improved symptoms and/or avoid symptom progression while approximately 1 in 50 will experience hypotension or dizziness. Mainly indirect comparisons suggest doxazosin and terazosin may be slightly more effective but have increased risk of adverse events.  



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • 15 systematic reviews of alpha-blockers in symptomatic BPH.1 
    • Versus placebo (26 Randomized Controlled Trials (RCTs)): Alpha-blockers:2 
      • Improved peak urinary flow (Qmax): 1.32 ml⁄s. 
      • Decreased symptoms [International Prostate Symptom Score (IPSS)]: -1.92. 
    • Network meta-analysis (124 RCTs)3 compared doxazosin, terazosinalfuzosin, and tamsulosin:  
      • Improved Qmax (ml/s): 1.951.211.07 and 1.07 respectively. 
      • Decreased IPSS by: -3.67, -3.37, -2.13, and -2.07 respectively. 
        • Doxazosin significantly better for both outcomes. 
      • Doxazosin and terazosin (non-uroselective): Significant increase in adverse events (dizziness and headache). 
  • Systematic review compares alpha-blockers to finasteride (alpha-reductase inhibitor). 
    • 23 RCTs (20,821 patients) finasteride:4 
      • Inferior to doxazosin and terazosin for Qmax and IPSS at one year. 
      • Non-inferior to tamsulosin. 
    • Finasteride and dutasteride similarly effective.5,6 
  • RCT (3,047 men) of placebo versus doxazosin, finasteride, or combination. Compared to placebo, doxazosin:7 
    • Reduced BPH symptom progression, Number Needed to Treat (NNT)=15 over four years. 
    • Increased hypotension (Number Needed to Harm (NNH)=58) and dizziness (NNH=48). 
  • Three pooled RCTs (955 patients):8 More men receiving alfuzosin (76%) reached point improvement on IPSS than placebo (62%), NNT=7. 
Context: 
  • Guidelines recommend alpha-blockers as first line therapy for symptomatic BPH.9,10 
  • Clinically meaningful improvement of IPSS is ≥2-6, depending on baseline.11 
  • Transurethral resection12,13 of the prostate improves Qmax 10-11 ml/s and decreases IPSS 16.7. 
  • Alpha blockers associated with increased risk of falls (NNT=589) and fracture (NNT=1,667).14 
  • 2013 systematic review comparing alpha-blockers to combination therapy with alpha reductase inhibitors: Combination therapy effective for enlarged prostates and treatment for >1 year.15 


Latest Tools for Practice
Derniers outils pour la pratique

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles

#361 Preventing RSV Infections in Infants

How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Christina Korownyk MD CCFP
  • Mathieos Belayneh

1. Yuan J, Liu Y, Yang Z, et al. Curr Med Res Opin. 2013; 29:279-87.

2. Nickel JC, Sander S, Moon TD. Int J Clin Pract. 2008; 62:1547-59.

3. Yuan JQ, Mao C, Wong SY, et al. Medicine (Baltimore). 2015; 94:e974.

4. Tacklind J, Fink HA, MacDonald R, et al. Cochrane Database Syst Rev. 2010; 10:CD006015

5. Nickel JC, Gilling P, Tammela TL, et al. BJU Int. 2011; 108:388-94.

6. Kaplan SA. J Urol. 2012; 187:584-5.

7. McConnell JD, Roehrborn CG, Bautista OM, et al. N Engl J Med. 2003; 349:2387-98.

8. Roehrborn CG, Van Kerrebroeck P, Nordling J. BJU Int. 2003; 92:257-61.

9. McVary KT, Roehrborn CG, Avins AL, et al. J Urol. 2011; 185(5):1793-803.

10. Nickel, JC, Méndez-Probst CE, Whelan TF, et al. Can Urol Assoc J. 2010 Oct; 4(5):310-6.

11. Barry MJ, Williford WO, Chang YC, et al. J Urol. 1995; 154:1770.

12. Milonas D, Verikaite J, Jievaltas M. Cent European J Urol. 2015; 68:169-74.

13. Reich O, Gratzke C, Bachmann A, et al. J Urol. 2008; 180:246-9.

14. Welk B, McArthur E, Fraser LA, et al. BMJ. 2015; 351:h5398.

15. Füllhase C, Chapple C, Cornu JN, et al. Eur Urol. 2013; 64:228-43.

Authors do not have any conflicts to disclose.